Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 23, 2026, 8:51 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Prostate Cancer Patients Clear all
Completed No phase listed Observational

Observational Cohort Study of Patients With Castration-Resistant Prostate Cancer (CRPC)

NCT02380274
View directory record Official record
Conditions
Prostate Cancer, Castration-resistant Prostate Cancer, Metastatic Prostate Cancer
Interventions
Not listed
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
18 Years and older · Male only
Enrollment
1,030 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
148
States / cities
Homewood, Alabama • Anchorage, Alaska • Phoenix, Arizona + 132 more
Source: ClinicalTrials.gov public record
Updated Nov 19, 2024 · Synced Jul 23, 2026, 8:51 AM EDT
Not yet recruiting Phase 2 Interventional

A Phase 2 Trial of 61Cu-NU101 PET/CT Compared Against Current Standard-of-care 18F-piflufolastat (Pylarify®) PET/CT.

NCT07635524
View directory record Official record
Conditions
Prostate Cancer
Interventions
Cu-NU101
Drug
Lead sponsor
Hoag Memorial Hospital Presbyterian
Other
Eligibility
18 Years and older · Male only
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
2
States / cities
Newport Beach, California • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 8, 2026 · Synced Jul 23, 2026, 8:51 AM EDT
Completed Phase 2 Interventional Results available

[F-18] Fluorothymidine PET/CT Imaging for Pelvic Cancers

NCT01717391
View directory record Official record
Conditions
Uterine Cervical Neoplasms, Endometrial Neoplasms, Anus Neoplasms, Rectal Neoplasms, Prostatic Neoplasms
Interventions
fluorothymidine F 18
Drug
Lead sponsor
John M. Buatti
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Mar 25, 2019 · Synced Jul 23, 2026, 8:51 AM EDT
Completed Phase 2 Interventional Results available

Sorafenib and Docetaxel in Patients With Prostate Cancer That Did Not Respond to Previous Hormone Therapy

NCT00589420
View directory record Official record
Conditions
Prostate Cancer
Interventions
docetaxel, sorafenib tosylate
Drug
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years to 120 Years · Male only
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 16, 2022 · Synced Jul 23, 2026, 8:51 AM EDT
Completed Phase 2 Interventional Results available

Tandutinib in Treating Patients With Progressive Prostate Cancer and Bone Metastases

NCT00390468
View directory record Official record
Conditions
Metastatic Cancer, Pain, Prostate Cancer
Interventions
Tandutinib
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Male only
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 27, 2014 · Synced Jul 23, 2026, 8:51 AM EDT
Terminated Phase 4 Interventional Results available

A Study of Enzalutamide Re-treatment in Metastatic Castration-resistant Prostate Cancer After Docetaxel and/or Cabazitaxel Treatment

NCT02441517
View directory record Official record
Conditions
Metastatic Castration Resistant Prostate Cancer
Interventions
Enzalutamide
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
18 Years and older · Male only
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
5
States / cities
Evanston, Illinois • Worcester, Massachusetts • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 18, 2018 · Synced Jul 23, 2026, 8:51 AM EDT
Terminated Phase 2 Interventional Results available

Cabazitaxel and Prednisone in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer

NCT02844582
View directory record Official record
Conditions
Hormone-Resistant Prostate Cancer, Stage IV Prostate Adenocarcinoma
Interventions
Cabazitaxel, Prednisone
Drug
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older · Male only
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Jan 24, 2021 · Synced Jul 23, 2026, 8:51 AM EDT
Not yet recruiting Phase 2 Interventional

Measuring Circulating Tumor Deoxyribonucleic Acid Tumor Fraction to Guide Early 177Lu-PSMA-617 Treatment Discontinuation in Patients With Metastatic Castration-Resistant Prostate Cancer, DYNAMO Trial

NCT07698535
View directory record Official record
Conditions
Metastatic Castration-Resistant Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8
Interventions
Lutetium Lu 177 Vipivotide Tetraxetan, Cell-free Circulating Tumor DNA Assay, Computed Tomography, Docetaxel, PSMA PET Scan, Single Photon Tomography and Computed Tomography Scan, Biospecimen Collection
Drug · Procedure
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older · Male only
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Jul 23, 2026, 8:51 AM EDT
Terminated Phase 2 Interventional

Efficacy and Safety Study of Etodolac and Propranolol in Patients With Clinically Progressive Prostate Cancer

NCT01857817
View directory record Official record
Conditions
Prostatic Neoplasms
Interventions
VT-122, Placebo
Drug
Lead sponsor
Vicus Therapeutics
Industry
Eligibility
18 Years and older · Male only
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
16
States / cities
Fayetteville, Arkansas • Santa Rosa, California • Parker, Colorado + 13 more
Source: ClinicalTrials.gov public record
Updated Apr 25, 2018 · Synced Jul 23, 2026, 8:51 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

A Study of Copanlisib Combined With Rucaparib in Patients With Metastatic Castration-resistant Prostate Cancer

NCT04253262
View directory record Official record
Conditions
Metastatic Castration-resistant Prostate Cancer
Interventions
Rucaparib, Copanlisib
Drug
Lead sponsor
Brown University
Other
Eligibility
18 Years and older · Male only
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
2
States / cities
San Francisco, California • Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated May 3, 2025 · Synced Jul 23, 2026, 8:51 AM EDT
Recruiting Not applicable Interventional

ASCVD Management Using CCTA in Prostate Cancer Patients on ADT

NCT05879913
View directory record Official record
Conditions
Prostate Cancer
Interventions
Coronary CT Angiography (CCTA)
Device
Lead sponsor
Indiana University
Other
Eligibility
40 Years and older · Male only
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
3
States / cities
Carmel, Indiana • Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Feb 24, 2026 · Synced Jul 23, 2026, 8:51 AM EDT
Completed Not applicable Interventional

Tolerability/Palatability of TalityTM Synthetic Meal Replacement in Prostate Cancer

NCT04389918
View directory record Official record
Conditions
Prostate Cancer
Interventions
Tality
Other
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older · Male only
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Feb 27, 2024 · Synced Jul 23, 2026, 8:51 AM EDT
Completed Phase 2 Interventional

Soy Supplements in Treating Patients Undergoing Surgery for Localized Prostate Cancer

NCT00345813
View directory record Official record
Conditions
Prostate Cancer
Interventions
soy isoflavones, soy protein isolate, placebo
Dietary Supplement · Other
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 120 Years · Male only
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 9, 2018 · Synced Jul 23, 2026, 8:51 AM EDT
Withdrawn Phase 2 Interventional

Neratinib in Patients With Metastatic Castration-Resistant Prostate Cancer

NCT04781374
View directory record Official record
Conditions
Metastatic Prostate Adenocarcinoma, Castration-resistant Prostate Cancer, Prostate Cancer, Prostate Cancer Metastatic
Interventions
Neratinib
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years and older · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
3
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 10, 2023 · Synced Jul 23, 2026, 8:51 AM EDT
Not listed Not applicable Interventional

ClariCore™ Biopsy System in Patients Undergoing Radical Retropubic Prostatectomy

NCT02773940
View directory record Official record
Conditions
Prostate Cancer
Interventions
ClariCore System
Device
Lead sponsor
Precision Biopsy, Inc.
Industry
Eligibility
18 Years to 85 Years · Male only
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
2
States / cities
Baltimore, Maryland • New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 14, 2019 · Synced Jul 23, 2026, 8:51 AM EDT
Completed Phase 1 Interventional

Motexafin Gadolinium and Doxorubicin in Treating Patients With Advanced Cancer

NCT00036790
View directory record Official record
Conditions
Breast Cancer, Chronic Myeloproliferative Disorders, Colorectal Cancer, Head and Neck Cancer, Leukemia, Lung Cancer, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic/Myeloproliferative Diseases, Prostate Cancer, Small Intestine Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
doxorubicin hydrochloride, motexafin gadolinium
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 120 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
2
States / cities
Pittsburgh, Pennsylvania • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Dec 16, 2019 · Synced Jul 23, 2026, 8:51 AM EDT
Recruiting No phase listed Observational

Circulating Tumor Cell Analysis in Patients With Localized Prostate Cancer Undergoing Prostatectomy

NCT01961713
View directory record Official record
Conditions
Prostate Cancer
Interventions
Not listed
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older · Male only
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 24, 2025 · Synced Jul 23, 2026, 8:51 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Decision Making in Unaffected First-Degree Relatives of Prostate Cancer Patients

NCT00815750
View directory record Official record
Conditions
Prostate Cancer
Interventions
Information Gathering, Decision Aid
Other
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
40 Years to 70 Years · Male only
Enrollment
147 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2014
U.S. locations
2
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Jul 30, 2014 · Synced Jul 23, 2026, 8:51 AM EDT
Active, not recruiting Not applicable Interventional

Rectal Spacers in Prostate Cancer Patients Undergoing Radiation Therapy

NCT06599476
View directory record Official record
Conditions
Prostate Cancer
Interventions
BioProtect Balloon Implant™ System
Device
Lead sponsor
Advanced Radiation Centers of New York
Other
Eligibility
18 Years and older · Male only
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
New Hyde Park, New York
Source: ClinicalTrials.gov public record
Updated Jun 24, 2026 · Synced Jul 23, 2026, 8:51 AM EDT
Completed No phase listed Observational

Proton-Based Stereotactic Ablative Body Radiotherapy for Prostate Cancer

NCT03159676
View directory record Official record
Conditions
Prostate Cancer
Interventions
Proton beam
Radiation
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older · Male only
Enrollment
150 participants
Timeline
2017 – 2024
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 24, 2026 · Synced Jul 23, 2026, 8:51 AM EDT
Completed Phase 2 Interventional Results available

Open Label Study to Assess Efficacy and Safety of Olaparib in Confirmed Genetic BRCA1 or BRCA2 Mutation Pats

NCT01078662
View directory record Official record
Conditions
Ovarian, Breast, Prostate, Pancreatic, Advanced Tumours
Interventions
olaparib
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
298 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2024
U.S. locations
2
States / cities
West Hollywood, California • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 12, 2025 · Synced Jul 23, 2026, 8:51 AM EDT
Not listed Phase 1 Interventional

Immunotherapy Study of Evofosfamide in Combination With Ipilimumab

NCT03098160
View directory record Official record
Conditions
Pancreatic Cancer, Melanoma, Squamous Cell Carcinoma of the Head and Neck, Prostate Cancer
Interventions
Evofosfamide, Ipilimumab
Drug
Lead sponsor
Threshold Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 29, 2017 · Synced Jul 23, 2026, 8:51 AM EDT
Completed Phase 3 Interventional

Chemotherapy in Treating Patients Who Have Metastatic Prostate Cancer

NCT00003343
View directory record Official record
Conditions
Prostate Cancer
Interventions
endocrine-modulating drug therapy, mitoxantrone hydrochloride, prednisone, prinomastat
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older · Male only
Enrollment
525 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1998
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Aug 7, 2012 · Synced Jul 23, 2026, 8:51 AM EDT
Completed Not applicable Interventional

TIPOPS (Telemedicine vs In Person Oncology Patient Surveillance)

NCT04936243
View directory record Official record
Conditions
Breast Cancer, Prostate Cancer, Patient Engagement, Patient Preference, Patient Satisfaction
Interventions
FOLLOW UP VISIT-TELEMEDICINE, FOLLOW UP VISIT-FACE TO FACE
Behavioral
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 19, 2022 · Synced Jul 23, 2026, 8:51 AM EDT